Can You Lower Lp(a)? The New Lipoprotein(a) Drugs | Philadelphia

Vijayakumar, Ashvin

TL;DR30-second take

Lipoprotein(a), or Lp(a), is an inherited cholesterol particle (>= 50 mg/dL or >= 125 nmol/L in 1 in 5 adults) that drives heart attacks, strokes, and aortic valve narrowing. Four new Phase 3 drugs - pelacarsen, olpasiran, lepodisiran, and oral muvalaplin - lower Lp(a) by 80 to 97%. However, in September 2026, the first Phase 3 outcomes trial (Lp(a)HORIZON with pelacarsen, ~80% reduction) missed its primary 4-point MACE endpoint, shifting attention to deeper 94 to 97% siRNA reducers like olpasiran (OCEAN(a)-Outcomes, due late 2026) and lepodisiran (ACCLAIM-Lp(a), due 2029). Today, driving ApoB below 50 mg/dL, keeping blood pressure under 120/80, and keeping hs-CRP under 1.0 mg/L cuts heart and vessel events by 50 to 65% even while Lp(a) stays high.

TL;DR:

What Lp(a) is: Lipoprotein(a) (>= 50 mg/dL or >= 125 nmol/L) is a genetically fixed particle carried by roughly 1 in 5 adults that increases the risk of heart attacks, ischemic stroke, and aortic valve stenosis.¹

The September 2026 Lp(a)HORIZON turning point: Pelacarsen (an injectable antisense drug that lowers Lp(a) ~80%) failed to meet its primary 4-point MACE endpoint in September 2026 (Lp(a)HORIZON, n = 8,323).² ³ That surprise result proves that lowering the lab number is not by default the same as preventing heart attacks - and puts the spotlight on olpasiran (OCEAN(a)-Outcomes, due late 2026) and lepodisiran (ACCLAIM-Lp(a), due 2029), which silence Lp(a) deeper (94 to 97%) and test heart-artery-focused endpoints.³ ⁴ ⁵

What works right now (50 to 65% risk drop): In EPIC-Norfolk (n = 17,087), UK Biobank (n = 385,917), and FOURIER/ODYSSEY, high-Lp(a) patients who drive ApoB < 50 mg/dL, keep blood pressure < 120/80 mmHg, and keep hs-CRP < 1.0 mg/L cut heart and vessel events by 50 to 65%. At the same time, PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) 19 to 30% and cut MACE by 23% (NNT = 40).⁶ ⁷ ⁸ ⁹

Aspirin and niacin truths: Low-dose aspirin (81 mg) cuts events by 56 to 76% in carriers of the LPA rs3798220-C genetic variant (WHS and ASPREE trials). In contrast, pooled cohorts (n = 23,662) show no blanket benefit from Lp(a) level alone (HR 1.01) without genotype or heart-artery calcium (CAC >= 100) selection.¹⁰ ¹¹ ¹² Never take niacin for Lp(a): it failed in HPS2-THRIVE (n = 25,673), raises diabetes (+32%) and bleeding (+38%), and generates the vessel-toxic metabolite 4PY.¹³ ¹⁴

Why has `Lp(a)` been so hard to treat - and what can you change today?

For decades, medicine could measure Lp(a) (>= 50 mg/dL or >= 125 nmol/L) but had no targeted drug to lower it safely. While targeted Phase 3 RNA and oral drugs now cut Lp(a) by 80 to 97%, your most powerful proven move today is crushing the changeable risks around it: driving ApoB below 50 mg/dL, holding blood pressure under 120/80 mmHg, and keeping hs-CRP below 1.0 mg/L.¹ ⁶ ⁷

Lipoprotein(a) is an LDL-like particle wrapped in a sticky protein tail called apolipoprotein(a). Because 80 to 90% of your Lp(a) level is locked in by your LPA gene at birth, diet and exercise barely move the number.¹ Statins do not lower Lp(a) (they can nudge it up by 5 to 15%), and niacin was abandoned after two massive outcome trials (AIM-HIGH and HPS2-THRIVE, n = 29,087 combined) proved it did not prevent heart attacks while causing diabetes, bleeding, and 4PY-driven vessel swelling.¹³ ¹⁴

Yet having an unchangeable Lp(a) number does not mean your heart attack risk is fixed. Across six randomized statin trials (Bhatia et al., Circulation 2025), EPIC-Norfolk (Verbeek 2018. Kraaijenhof 2025, n = 17,087), and the UK Biobank (Wang et al., 2025, n = 385,917), Lp(a) acts as a risk multiplier on top of ApoB, blood pressure, and vessel swelling (hs-CRP):⁶ ⁷ ¹⁵ ¹⁶

When LDL-C (ApoB), hs-CRP, and Lp(a) are all high together, heart and vessel risk jumps 2.41-fold (HR 2.41).⁶
When high-Lp(a) adults (>= 125 nmol/L) keep their changeable heart and vessel health high (Life's Simple 7 >= 10) and drive ApoB and LDL-C down aggressively, their excess heart and vessel event rate drops by 50 to 65% (HR 0.35).⁷ ¹⁶ ¹⁷
In the FOURIER (n = 25,096) and ODYSSEY OUTCOMES (n = 18,924) trials, adding a PCSK9 inhibitor (evolocumab or alirocumab) to a statin lowered LDL-C by 50 to 60% and trimmed Lp(a) by 19 to 30%, cutting major adverse heart and vessel events by 23% (NNT = 40 over 3 years) in patients with high baseline Lp(a).⁸ ⁹

High Lp(a) Action Plan Today & The Phase 3 Drug Pipeline

How do the four new Phase 3 `Lp(a)` drugs work - and what happened in `Lp(a)HORIZON`?

Four targeted drugs have reached Phase 3 trials: three injectable gene-silencers (pelacarsen, olpasiran, lepodisiran) that block the liver from building apolipoprotein(a) (80 to 97% reduction), and one daily oral pill (muvalaplin) that blocks the particle from assembling (~86% reduction). In September 2026, pelacarsen's Lp(a)HORIZON trial missed its primary 4-point MACE endpoint, making the deeper 94 to 97% siRNA trials the decisive test for the class.² ³ ⁴ ⁵ ¹⁸

Instead of trying to clear finished Lp(a) particles from the bloodstream, the new therapies stop Lp(a) production inside the liver cell (hepatocyte):

Drug (Sponsor)	Mechanism & Route	Dosing Schedule	`Lp(a)` Reduction	Phase 3 Outcomes Trial (`n`) & Population	Primary Readout Status
Pelacarsen (Novartis / Ionis)	Antisense oligonucleotide (`ASO`) degrading `LPA` mRNA (SubQ injection)	`80 mg` once monthly	`~80%`	`Lp(a)HORIZON` (`n = 8,323`): Prior MI, stroke, or PAD + `Lp(a) >= 70 mg/dL`	Sept 2026: Did NOT meet primary 4-point MACE endpoint.² ³
Olpasiran (Amgen)	Small interfering RNA (`siRNA`) via `RISC` complex (SubQ injection)	`225 mg` every 12 weeks (quarterly)	`~94 to 97%`	`OCEAN(a)-Outcomes` (`n = 7,297`): Prior CAD + `Lp(a) >= 200 nmol/L` (`~80-90 mg/dL`)	Expected ~December 2026 (plus `OCEAN(a)-PreEvent` in `~11,000` first-event patients due `~2031`).⁴
Lepodisiran (Eli Lilly)	Ultra-long-acting `GalNAc-siRNA` (SubQ injection)	`400 mg` every 6 to 12 months	`~94%` over days 60-180	`ACCLAIM-Lp(a)` (`n = 17,300`): Established ASCVD or high-risk primary prevention + `Lp(a) >= 175 nmol/L`	Estimated March 2029.⁵
Muvalaplin (Eli Lilly)	Small-molecule oral blocker preventing `apo(a)` from binding `apoB-100`	`60-240 mg` daily oral pill	`~85.8%` (intact `Lp(a)` assay)	`MOVE-Lp(a)` (`n = 10,450`): Prior ASCVD or high-risk primary prevention + `Lp(a) >= 175 nmol/L`	Estimated March 2031.¹⁸

Why did `Lp(a)HORIZON` (`pelacarsen`) miss its primary endpoint in September 2026 - and could `olpasiran` or `lepodisiran` still succeed?

In September 2026, Novartis announced that Lp(a)HORIZON (n = 8,323) did not achieve a clear win on its primary 4-point MACE composite (heart and vessel death, non-fatal MI, non-fatal stroke, or urgent heart-artery revascularization).² ³ That result is a sobering reminder of why we never treat an unapproved drug as a guaranteed cure before outcome trials finish.

At the same time, lipidologists point to three biological differences that explain why OCEAN(a)-Outcomes (olpasiran, expected late 2026) and ACCLAIM-Lp(a) (lepodisiran) could still succeed:³ ⁴ ⁵

Deeper Lp(a) suppression (94-97% vs ~80%): Mendelian randomization estimates suggest you need an absolute Lp(a) drop of 50 to 100 mg/dL (~125 to 250 nmol/L) to match the ~22% relative risk reduction of a 38.7 mg/dL (1 mmol/L) LDL-C drop.¹ In someone starting at 80 mg/dL, an 80% drop leaves residual Lp(a) around 16 mg/dL. In contrast, a 95 to 97% siRNA reduction drives Lp(a) nearly to zero (< 3-5 mg/dL).³ ⁴
Higher baseline entry threshold (>= 200 nmol/L): OCEAN(a)-Outcomes enrolled patients with Lp(a) >= 200 nmol/L (~80-90 mg/dL), guaranteeing a larger absolute particle reduction than Lp(a)HORIZON's >= 70 mg/dL cutoff.³ ⁴
heart-artery-focused primary endpoint: Lp(a)HORIZON included non-fatal stroke in its 4-point primary composite (where non-atherosclerotic strokes can dilute a lipid signal). In contrast, OCEAN(a)-Outcomes uses a pure 3-point heart-artery endpoint (heart-artery heart disease death, myocardial infarction, or urgent heart-artery revascularization).³ ⁴

A critical lab caveat on oral `muvalaplin`

Muvalaplin (KRAKEN Phase 2 trial, Nicholls et al., JAMA 2025) is the first daily oral pill for Lp(a).¹⁸ Because it works by binding free apo(a) tails so they cannot attach to apoB-100, standard commercial lab tests that measure total apo(a) protein count those harmless drug-bound apo(a) fragments and underestimate the true drop (~70% on standard assays vs 85.8% on an intact Lp(a) particle assay).¹⁸

Should you take low-dose aspirin (`81 mg`) or niacin if your `Lp(a)` is high?

Never take niacin for high Lp(a) - it failed to reduce events in 29,000+ patients and generates a toxic vessel metabolite (4PY).¹³ ¹⁴ Low-dose aspirin (81 mg) is not a blanket rule for everyone with Lp(a) >= 50 mg/dL, but it strongly reduces events (56 to 76% reduction) in carriers of the LPA rs3798220-C genetic variant and is favored when high Lp(a) coexists with heart-artery plaque (CAC >= 100) and low bleeding risk.¹⁰ ¹¹ ¹² ¹⁹

1. The Low-Dose Aspirin (`81 mg`) Nuance: Genotype vs. Mass Level

Because apolipoprotein(a) mimics plasminogen and slows clot breakdown, doctors long wondered whether daily aspirin (81 to 100 mg) could defuse Lp(a) thrombosis risk. The evidence splits sharply depending on how you select the patient:

Strong protection in LPA rs3798220-C variant carriers (HR 0.24 to 0.44): In post-hoc genetic analyses of two randomized placebo-controlled aspirin trials - the Women's Health Study (Chasman et al., 2009, n = 25,131) and ASPREE (Lacaze et al., JACC 2022, n = 12,815 older adults) - carriers of the rs3798220-C variant randomized to low-dose aspirin had a 56% reduction in heart and vessel events in WHS (HR 0.44) and a 76% reduction in MACE in ASPREE (HR 0.24, 95% CI 0.07-0.82) without significant excess major bleeding.¹⁰ ¹¹
Mixed results when using Lp(a) >= 50 mg/dL mass level alone: While a single-cohort propensity analysis in MESA (Bhatia et al., JAHA 2024, n = 2,183) suggested a 46% lower CHD rate (HR 0.54) with aspirin in adults with Lp(a) > 50 mg/dL,²⁰ a much larger 2025 pooled analysis of ARIC, CHS, and MESA (Colantonio et al., Eur J Prev Cardiol 2025, n = 23,662) found no overall reduction in CVD (HR 1.12) or CHD events (HR 1.01) from aspirin based on Lp(a) >= 50 mg/dL alone.¹² A 2026 meta-analysis (Lopes et al., EJPC 2026, n = 6,628) confirmed that significant MACE reduction was proven in rs3798220-C carriers (HR 0.37) instead of unselected mass-high cohorts (HR 0.62, non-significant).²¹
How we decide in the clinic: Following the 2024 NLA Update and 2026 ACC/AHA guidance, we do not put every 35-year-old with Lp(a) = 60 mg/dL and zero plaque on aspirin by default.¹⁹ Instead, we favor 81 mg daily aspirin when high Lp(a) is paired with heart-artery plaque on imaging (CAC >= 100, non-calcified plaque on CCTA, or CAC > 0 with Lp(a) >= 125 nmol/L) or confirmed rs3798220-C carrier status, provided bleeding risk is low.¹¹ ¹⁹

2. Why Niacin (`Vitamin B3`) Is Off the table for `Lp(a)`

High-dose niacin (1.5 to 2 g/day) lowers Lp(a) on a lab report by 20 to 25%,²² which still tempts some supplement protocols. Do not use it:

Zero heart and vessel benefit in 29,087 patients: Both AIM-HIGH (n = 3,414, HR 1.02) and HPS2-THRIVE (NEJM 2014, n = 25,673, RR 0.96, p = 0.29) showed zero reduction in heart attacks or strokes when extended-release niacin was added to statin therapy.¹³
Serious clinical harms: In HPS2-THRIVE, niacin sharply increased new-onset diabetes by +32% (RR 1.32), diabetic complications (+55%), serious bleeding (+38%, including intracranial and GI hemorrhage), serious infections (+22%), and gout.¹³
The 4PY vessel toxin discovery (Ferrell et al., Nature Medicine 2024): Excess niacin is broken down into a terminal metabolite called 4PY (N1-methyl-4-pyridone-3-carboxamide), which directly triggers VCAM-1 vessel swelling on artery walls and on its own predicts heart attacks and strokes.¹⁴ That explains the niacin paradox: the toxic 4PY swelling cancels out the 20% Lp(a) drop.

Guidance from the Clinic

"The September 2026 Lp(a)HORIZON readout was a reality check for preventive cardiology: `pelacarsen` lowered Lp(a) by 80% and still missed its primary 4-point MACE endpoint. That does not mean the Lp(a) pipeline is over - `olpasiran` and `lepodisiran` silence Lp(a) by 94 to 97% and test cleaner heart-artery endpoints - but it proves why you should never rest around waiting for a future injection to save you. When a patient in my practice has an Lp(a) of 180 nmol/L, we defang it today: we drive ApoB below 50 mg/dL, hold home blood pressure below 120/80, keep hs-CRP below 1.0 mg/L, check the arteries directly with a CCTA or CAC scan after 40, and decide on 81 mg aspirin based on whether plaque or the rs3798220-C variant is present. That global strategy cuts heart events by 50 to 65% right now."

Actionable Steps: Your `If -> Then` High-`Lp(a)` Playbook

Use these four If -> Then triggers if your Lp(a) is >= 50 mg/dL (>= 125 nmol/L):

If your Lp(a) is >= 125 nmol/L (>= 50 mg/dL) -> drive your ApoB below 50 mg/dL and hs-CRP below 1.0 mg/L: Low-dose rosuvastatin (5 to 10 mg) plus ezetimibe (10 mg) typically drops ApoB by 50 to 60%. if ApoB remains above 50 mg/dL or plaque is present, adding a PCSK9 inhibitor (evolocumab or alirocumab) drops ApoB another 50% while trimming Lp(a) by 19 to 30% (NNT = 40 in FOURIER).⁶ ⁸ ⁹
If you are over age 40 with high Lp(a) -> image your heart-artery arteries (CCTA or CAC): Because Lp(a) accelerates non-calcified soft plaque before calcium appears, a standard heart-artery CT Angiogram (CCTA) or heart-artery Calcium Score (CAC) tells us whether your arteries are clear or actively building plaque.¹⁹
If your scan shows heart-artery plaque (CAC >= 100 or soft plaque on CCTA) or you carry the LPA rs3798220-C variant -> discuss 81 mg daily aspirin: With low bleeding risk, low-dose aspirin offsets Lp(a)'s clot-stabilizing tail where genotype (HR 0.24-0.44) or visible atheroma confirms high absolute risk.¹⁰ ¹¹ ¹⁹
If someone recommends high-dose niacin (Vitamin B3) for Lp(a) -> stop it immediately: Niacin failed in 29,087 trial patients, raises diabetes (+32%) and bleeding (+38%), and produces the 4PY metabolite that inflames blood vessels (VCAM-1).¹³ ¹⁴

Lp(a): The Genetic Risk Most Panels Miss - what Lp(a) is, the I-676 traffic model, and family cascade testing
ApoB and Heart Health - the cholesterol particle target (< 50 mg/dL) to drive down alongside Lp(a)
Beyond Statins: PCSK9 Inhibitors, Ezetimibe & Bempedoic Acid - how PCSK9 inhibitors lower ApoB 50-60% and Lp(a) 20-30%
heart-artery Calcium Score (CAC) vs. CCTA - checking whether Lp(a) has laid down soft or calcified plaque
Heart Imaging Guide (CAC, CCTA, Cleerly) - choosing the right scan when Lp(a) is high
Lp(a) and Cholesterol - why a normal standard lipid panel hides high Lp(a)

Scientific References

Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. PMID: 36036785.
Sabouret P, et al. Lipoprotein(a)-targeted therapies after Lp(a)HORIZON: lessons from the first Phase 3 outcomes readout. Am J Med. 2026. PMID: 42880684.
Parcha V, Bittner VA. Lipoprotein(a)-Lowering Therapies in Clinical Trials: From Antisense Oligonucleotides to siRNAs and Oral Small Molecules. Curr Atheroscler Rep. 2026. DOI: 10.1007/s11883-026-01474-4.
O'Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease (OCEAN[a]-DOSE). N Engl J Med. 2022;387(20):1855-1864. DOI: 10.1056/NEJMoa2211023.
Nissen SE, Ni W, Shen X, et al. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). N Engl J Med. 2025;392(17):1673-1683. DOI: 10.1056/NEJMoa2415818.
Kraaijenhof JM, et al. Twenty-Year Cardiovascular Risk Associated With Combined Elevation of LDL Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) in EPIC-Norfolk. Eur Heart J. 2025. PMID: 40167249.
Wang M, et al. Joint associations of lipoprotein(a) and low-density lipoprotein cholesterol with incident coronary artery disease in 385,917 UK Biobank participants. Int J Epidemiol. 2025. PMID: 40064167.
O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial. Circulation. 2019;139(12):1483-1492. PMID: 30586750.
Schwartz GG, Ballantyne CM, Barter PJ, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome (ODYSSEY OUTCOMES). J Am Coll Cardiol. 2021;78(5):421-433. PMID: 34325831.
Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy in the Women's Health Study. Atherosclerosis. 2009;203(2):371-376. PMID: 18775538.
Lacaze P, Bakshi A, Riaz M, et al. Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes (ASPREE). J Am Coll Cardiol. 2022;80(14):1287-1298. PMID: 36175048.
Colantonio LD, et al. Aspirin use and cardiovascular events among adults with high lipoprotein(a): a pooled analysis of ARIC, CHS, and MESA. Eur J Prev Cardiol. 2025. PMID: 40874494.
HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med. 2014;371(3):203-212. DOI: 10.1056/NEJMoa1300955.
Ferrell M, Wang Z, Anderson JT, et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat Med. 2024;30(2):424-434. DOI: 10.1038/s41591-023-02793-8.
Bhatia HS, et al. Independent and Additive Cardiovascular Risk of Lipoprotein(a) and LDL Cholesterol Across Six Randomized Statin Trials. Circulation. 2025. PMC: PMC11771346.
Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with high lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39(27):2589-2596. PMID: 29931232.
Razavi AC, et al. Ideal Cardiovascular Health Attenuates Lipoprotein(a)-Associated Atherosclerotic Cardiovascular Disease Risk. Diabetes Obes Metab. 2025. DOI: 10.1111/dom.16469.
Nicholls SJ, Ni W, Rhodes GM, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial (KRAKEN). JAMA. 2025;333(3):222-231. DOI: 10.1001/jama.2024.24017.
Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. PMID: 38565461.
Bhatia HS, Trainor P, Carlisle S, et al. Aspirin and Cardiovascular Risk in Individuals With high Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2024;13(3):e033562. PMID: 38293935.
Lopes RD, et al. Aspirin for Primary Cardiovascular Prevention in high Lipoprotein(a) and LPA Risk Genotypes: A Systematic Review and Meta-Analysis. Eur J Prev Cardiol. 2026. PMID: 42138694.
Sahebkar A, Reiner Ž, Simental-Mendía LE, Ferretti G, Cicero AFG. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016;65(11):1664-1678. PMID: 27733255.

Fishtown Medicine | Cardiovascular risk

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

With currently FDA-approved medications, `PCSK9` inhibitors (`evolocumab` / Repatha and `alirocumab` / Praluent) lower `Lp(a)` by `19 to 30%` while cutting `LDL-C` and `ApoB` by `50 to 60%`.89 Trial-stage Phase 3 drugs (`pelacarsen`, `olpasiran`, `lepodisiran`, and oral `muvalaplin`) lower `Lp(a)` by `80 to 97%`, though none is FDA-approved yet.34518

In September 2026, Novartis reported that `Lp(a)HORIZON` (`n = 8,323` patients with prior heart and vessel disease and `Lp(a) >= 70 mg/dL`) did not reach a clear win on its primary 4-point MACE endpoint with monthly `pelacarsen` (`~80%` `Lp(a)` reduction).23 Attention now centers on `OCEAN(a)-Outcomes` (`olpasiran`, expected late 2026) and `ACCLAIM-Lp(a)` (`lepodisiran`, due 2029), which achieve deeper `94 to 97%` `Lp(a)` reductions in patients with higher baseline `Lp(a)` (`>= 175-200 nmol/L`).345

By `50 to 65%`. In `EPIC-Norfolk` (`n = 17,087`) and `UK Biobank` (`n = 385,917`), high-`Lp(a)` individuals who kept `ApoB` (`LDL-C`), blood pressure (`< 120/80 mmHg`), `hs-CRP` (`< 1.0 mg/L`), and metabolic health optimal eliminated roughly two-thirds of the excess heart and vessel risk associated with high `Lp(a)`.<a href="#ref-6" class="underline decoration-1 underline-offset-2 text-brand-primary hover:text-brand-primary transition-colors">6716

Not by default based on the blood level alone. While carriers of the `LPA rs3798220-C` genetic variant saw a `56 to 76%` reduction in heart and vessel events with low-dose aspirin in `WHS` and `ASPREE`,1011 a 2025 pooled analysis of `23,662` adults (`ARIC`, `CHS`, `MESA`) found no overall CVD reduction (`HR 1.12`) when selecting by `Lp(a) >= 50 mg/dL` alone without genotype.12 We prescribe `81 mg` aspirin when high `Lp(a)` is paired with heart-artery plaque (`CAC >= 100` or soft plaque on `CCTA`) or `rs3798220-C` positivity and low bleeding risk.19

Deep-Dive Questions

Statins upregulate `LDL` receptors on liver cells, which rapidly clear standard `LDL` and `ApoB` particles (`-40 to 55%`) but play a minimal role in clearing `Lp(a)`. Even though statins can nudge `Lp(a)` up by `5 to 15%`, a patient-level meta-analysis of 6 randomized statin trials (`Bhatia et al., Circulation 2025`) proved that lowering `LDL-C`/`ApoB` sharply reduces absolute heart attack risk at every tier of `Lp(a)`.15 Pairing a low-dose statin with ezetimibe (and a `PCSK9` inhibitor when needed) removes the changeable `ApoB` traffic so `Lp(a)` has less substrate to inflame.

Olpasiran and `lepodisiran` are small interfering RNAs (`siRNAs`) injected under the skin every 3 to 12 months that destroy `LPA` mRNA inside the liver before the `apo(a)` protein is ever translated (`94 to 97%` reduction).45 Muvalaplin is a daily oral small-molecule pill that binds the kringle domains (`KIV7-KIV8`) of the `apo(a)` protein and physically blocks it from attaching to `apoB-100` (`85.8%` reduction in intact `Lp(a)` particles in the Phase 2 `KRAKEN` trial).18

Early Phase 3 trials (`Lp(a)HORIZON` and `OCEAN(a)-Outcomes`) enrolled patients who had *already* suffered a heart attack, stroke, or peripheral artery event. `ACCLAIM-Lp(a)` (`lepodisiran`, `n = 17,300`, completing 2029) and `OCEAN(a)-PreEvent` (`olpasiran`, `n ~ 11,000`, completing 2031) are the first massive trials testing whether silencing `Lp(a)` prevents a *first* heart attack in high-risk first-event adults.45

Ready when you are